Asieris Announces the Completion of their Series D Round of Financing

Shanghai, China, November 11, 2020 – Asieris Pharmaceuticals is a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases.

Today they announced the completion of their Series D Round of financing. This round of funding was led by Qiming Venture Partners, and joined by YF Capital, CICC Transfer Fund, V-Capital, Hengxu Capital, Homsun Capital, Gopher Asset Management, C&D Emerging Capital, HighRUN Capital, Triwise Capital, IN CAPITAL, Haoshuo Zhier Fund, and IFSC.

In total, the transaction amount exceeded 700 million Chinese yuan.